Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Tactile Systems reports Q3 growth, faces documentation challenges and opportunities

Tactile Systems delivered solid Q3 performance with revenue growth and improved EBITDA, despite challenges in sales productivity.
The company's strategic strengths lie in strong market demand, product innovation, and a shareholder-friendly capital allocation strategy.
Navigating challenges related to regulatory changes and operational efficiency while capitalizing on growth opportunities will be key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Option Care Health

Vericel

The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.

The 3 Highest-Rated Medical Stocks You Can Buy Today

MINNEAPOLIS, May 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 44th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL from June 4th - 6th. Management will participate in a fireside chat on Tuesday, June 4th at 9:20 a.m. Central Time.

Tactile Medical to Present at the William Blair 44th Annual Growth Stock Conference

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants Sam Bentzinger – Investor Relations-Gilmartin Group LLC Dan Reuvers – President and Chief Executive Officer Elaine Birkemeyer – Chief Financial Officer Conference Call Participants Adam Maeder – Piper Sandler Margaret Kaczor – William Blair Suraj Kalia – Oppenheimer & Company Ryan Zimmerman – BTIG Operator Welcome, ladies and gentlemen, to the First Quarter 2024 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.

Tactile Systems Technology, Inc. (TCMD) Q1 2024 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.03 per share a year ago.

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Summary: Total revenue increased 4% year-over-year to $61.1 million Lymphedema product revenue increased 5% year-over-year Airway clearance product revenue decreased 4% year-over-year Net loss of $2.2 million versus $1.9 million in Q1 2023 Adjusted EBITDA of $1.0 million versus $0.5 million in Q1 2023 Recent Business Highlights: Completed enrollment of 235 patients in a multi-center, randomized clinical trial evaluating Flexitouch Plus for the treatment of head and neck lymphedema patients Journal of Vascular Surgery published largest ever peer-reviewed clinical trial investigating Flexitouch use among lymphedema patients, revealing improvements in quality of life, limb girth, and cellulitis events Announced upcoming retirement of Dan Reuvers and appointment of Sheri Dodd as President and CEO, effective July 1, 2024 “We were pleased with our overall first quarter performance.

Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results

Tactile Systems Technology (TCMD) concluded the recent trading session at $14.44, signifying a +0.7% move from its prior day's close.

Tactile Systems Technology (TCMD) Rises But Trails Market: What Investors Should Know

Zacks.com users have recently been watching Tactile Systems Technology (TCMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Tactile Systems Technology, Inc. (TCMD): Here is What You Need to Know

Tactile Systems Technology (TCMD) concluded the recent trading session at $14.30, signifying a +0.21% move from its prior day's close.

Tactile Systems Technology (TCMD) Increases Yet Falls Behind Market: What Investors Need to Know

MINNEAPOLIS, April 23, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Dan Reuvers will retire as the Company's Chief Executive Officer, effective June 30, 2024. Concurrently, the Company announced the appointment of Sheri Dodd, a member of the Company's board of directors, as Chief Executive Officer, effective July 1, 2024. Following such date, Mr. Reuvers will serve as an advisor to Ms. Dodd through March 31, 2025 in support of the transition, as well as remain a member of the Company's board of directors.

Tactile Medical Announces CEO Transition and Preliminary First Quarter 2024 Revenue

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts See Tactile Systems Technology (TCMD) as a Buy: Should You Invest?

Tactile Systems Technology (TCMD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Tactile Systems Technology, Inc. (TCMD) is a Trending Stock

Applied Materials

Portillo's

Quad/Graphics

TCMD, QUAD, YPF, AMAT and PTLO have been added to the Zacks Rank #1 (Strong Buy) List on April 16, 2024.

New Strong Buy Stocks for April 16th

MINNEAPOLIS, April 15, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2024 financial results will be released after the market closes on Monday, May 6, 2024.

Tactile Medical to Release First Quarter of Fiscal Year 2024 Financial Results on May 6, 2024

In the closing of the recent trading day, Tactile Systems Technology (TCMD) stood at $14.78, denoting a -1.79% change from the preceding trading day.

Tactile Systems Technology (TCMD) Declines More Than Market: Some Information for Investors

Enphase Energy

IDEXX Laboratories

Paycom Software

Revolve

Simulations Plus

Vicor

You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.

New AI Bot Predicts These 7 Stocks Will Mint Millionaires

Constellium NV Class A

Greif

Blue Owl Capital

Texas Pacific Land Trust

CSTM, TCMD, GEF, OWL and TPL have been added to the Zacks Rank #1 (Strong Buy) List on April 5, 2023.

New Strong Buy Stocks for April 5th

Tactile Systems Technology (TCMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Tactile Systems Technology (TCMD) Upgraded to Strong Buy: Here's What You Should Know

By 2024, one of the best-known traits shared by many U.S. politicians has become their uncanny ability to trade the right stocks at the right time – or their courage to engage in insider trading,  as some, like “The Wolf of Wall Street” Jordan Belfort have suggested.

‘Most suspicious congressional trade' of 2023 now up 63% in 5 months

The mean of analysts' price targets for Tactile Systems Technology (TCMD) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 29.76% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?

Due to their appeal, US politicians and their insider trades rarely go unnoticed by the trading community. However, some trades fly under the radar, as is the case with Senator Tina Smith's trade.

This US politician's super suspicious trade goes unnoticed

The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 30.49%: Read This Before Placing a Bet

After losing some value lately, a hammer chart pattern has been formed for Tactile Systems Technology (TCMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Tactile Systems Technology (TCMD) Could be Great Choice for a Bottom Fisher

Tactile Systems Technology announced mixed fourth-quarter results, beating earnings estimates and falling slightly short on revenue. The medical technology company is enjoying strong operating leverage despite modest revenue growth.

Why Tactile Systems Technology Stock Dropped Today

Tactile Systems Technology (TCMD) Q4 2023 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.29 per share a year ago.

News for Tactile Systems Stock (TCMD)